Literature DB >> 21357293

Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolates.

Maiken Cavling Arendrup1, Steven Park, Steven Brown, Michael Pfaller, David S Perlin.   

Abstract

Disk diffusion testing has recently been standardized by the CLSI, and susceptibility breakpoints have been established for several antifungal compounds. For caspofungin, 5-μg disks are approved, and for micafungin, 10-μg disks are under evaluation. We evaluated the performances of caspofungin and micafungin disk testing using a panel of Candida isolates with and without known FKS echinocandin resistance mechanisms. Disk diffusion and microdilution assays were performed strictly according to CLSI documents M44-A2 and M27-A3. Eighty-nine clinical Candida isolates were included: Candida albicans (20 isolates/10 mutants), C. glabrata (19 isolates/10 mutants), C. dubliniensis (2 isolates/1 mutant), C. krusei (16 isolates/3 mutants), C. parapsilosis (14 isolates/0 mutants), and C. tropicalis (18 isolates/4 mutants). Quality control strains were C. parapsilosis ATCC 22019 and C. krusei ATCC 6258. The correlations between zone diameters and MIC results were good for both compounds, with identical susceptibility classifications for 93.3% of the isolates by applying the current CLSI breakpoints. However, the numbers of fks hot spot mutant isolates misclassified as being susceptible (S) (very major errors [VMEs]) were high (61% for caspofungin [S, ≥11 mm] and 93% for micafungin [S, ≥14 mm]). Changing the disk diffusion breakpoint to S at ≥22 mm significantly improved the discrimination. For caspofungin, 1 VME was detected (a C. tropicalis isolate with an F76S substitution) (3.5%), and for micafungin, 10 VMEs were detected, the majority of which were for C. glabrata (8/10). The broadest separation between zone diameter ranges for wild-type (WT) and mutant isolates was seen for caspofungin (6 to 12 mm versus -4 to 7 mm). In conclusion, caspofungin disk diffusion testing with a modified breakpoint led to excellent separation between WT and mutant isolates for all Candida species.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357293      PMCID: PMC3088242          DOI: 10.1128/AAC.01373-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.

Authors:  Santosh Katiyar; Michael Pfaller; Thomas Edlind
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

2.  Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media.

Authors:  Maiken Cavling Arendrup; Guillermo Garcia-Effron; Cornelia Lass-Flörl; Alicia Gomez Lopez; Juan-Luis Rodriguez-Tudela; Manuel Cuenca-Estrella; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

3.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

4.  Detection of caspofungin resistance in Candida spp. by Etest.

Authors:  Marie Desnos-Ollivier; Françoise Dromer; Eric Dannaoui
Journal:  J Clin Microbiol       Date:  2008-04-30       Impact factor: 5.948

5.  Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.

Authors:  Marie Desnos-Ollivier; Stéphane Bretagne; Dorothée Raoux; Damien Hoinard; Françoise Dromer; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

6.  Caspofungin disk diffusion breakpoints and quality control.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2008-04-09       Impact factor: 5.948

7.  Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.

Authors:  Maiken Cavling Arendrup; Guillermo Garcia-Effron; Walter Buzina; Klaus Leth Mortensen; Nanna Reiter; Christian Lundin; Henrik Elvang Jensen; Cornelia Lass-Flörl; David S Perlin; Brita Bruun
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

8.  Acquired resistance to echinocandins in Candida albicans: case report and review.

Authors:  Marie-Thérèse Baixench; Naji Aoun; Marie Desnos-Ollivier; Dea Garcia-Hermoso; Stéphane Bretagne; Sandrine Ramires; Christophe Piketty; Eric Dannaoui
Journal:  J Antimicrob Chemother       Date:  2007-04-27       Impact factor: 5.790

9.  Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.

Authors:  Michel Laverdière; Richard G Lalonde; Jean-Guy Baril; Donald C Sheppard; Steven Park; David S Perlin
Journal:  J Antimicrob Chemother       Date:  2006-02-07       Impact factor: 5.790

10.  Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.

Authors:  Guillermo Garcia-Effron; Samuel Lee; Steven Park; John D Cleary; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

View more
  12 in total

1.  Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria.

Authors:  Michael A Pfaller; Daniel J Diekema; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

Review 2.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

3.  Evaluation of Two Commercial Broth Microdilution Methods Using Different Interpretive Criteria for the Detection of Molecular Mechanisms of Acquired Azole and Echinocandin Resistance in Four Common Candida Species.

Authors:  Ha Jin Lim; Jong Hee Shin; Mi-Na Kim; Dongeun Yong; Seung A Byun; Min Ji Choi; Seung Yeob Lee; Eun Jeong Won; Seung-Jung Kee; Soo Hyun Kim; Myung-Geun Shin
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

4.  Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.

Authors:  Michael A Pfaller; Shawn A Messer; Daniel J Diekema; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-10-23       Impact factor: 5.948

5.  Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis.

Authors:  Antonietta Vella; Elena De Carolis; Luisa Vaccaro; Patrizia Posteraro; David S Perlin; Markus Kostrzewa; Brunella Posteraro; Maurizio Sanguinetti
Journal:  J Clin Microbiol       Date:  2013-07-03       Impact factor: 5.948

6.  Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.

Authors:  Maiken Cavling Arendrup; David S Perlin; Rasmus Hare Jensen; Susan Julie Howard; Joanne Goodwin; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

7.  Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species.

Authors:  Karen M Astvad; David S Perlin; Helle K Johansen; Rasmus H Jensen; Maiken C Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

8.  Comparative analysis of calcineurin signaling between Candida dubliniensis and Candida albicans.

Authors:  Jing Zhang; Joseph Heitman; Ying-Lien Chen
Journal:  Commun Integr Biol       Date:  2012-03-01

9.  Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans.

Authors:  Kevin Kim; Leeor Zilbermintz; Mikhail Martchenko
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-06-09       Impact factor: 3.944

10.  Polishing the Therapy of Onychomycosis Induced by Candida spp.: Amphotericin B-Loaded Nail Lacquer.

Authors:  Aleph M S Souza; Renato C A Ribeiro; Gleyse K L O Pinheiro; Francisco I Pinheiro; Wógenes N Oliveira; Luanda B F C Souza; André L Silva; Lucas Amaral-Machado; Éverton N Alencar; Guilherme M Chaves; Eryvaldo S T Egito
Journal:  Pharmaceutics       Date:  2021-05-24       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.